Optimized cocktail of 90Y/177Lu for radionuclide therapy of neuroendocrine tumors of various sizes: a simulation study

被引:1
|
作者
Peer-Firozjaei, Milad [1 ]
Tajik-Mansoury, Mohammad Ali [1 ,2 ]
Geramifar, Parham [3 ]
Ghorbani, Raheb [4 ]
Zarifi, Shiva [1 ]
Miller, Cassandra [5 ,6 ]
Rahmim, Arman [5 ,6 ]
机构
[1] Semnan Univ Med Sci, Fac Med, Dept Med Phys, Semnan 1985717443, Iran
[2] Shahid Beheshti Univ Med Sci SBMU, Sch Med, Dept Biomed Engn & Med Phys, Tehran, Iran
[3] Univ Tehran Med Sci, Shariati Hosp, Res Ctr Nucl Med, Nucl Med Dept, Tehran, Iran
[4] Semnan Univ Med Sci, Dept Epidemiol & Biostat, Fac Med, Social Determinants Hlth Res Ctr, Semnan, Iran
[5] BC Canc Res Inst, Dept Integrat Oncol, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada
关键词
radioisotope cocktail; tumor dosimetry; Lu-177; Y-90; DOSIMETRY; RADIOTHERAPY;
D O I
10.1097/MNM.0000000000001546
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background and objectives There is significant interest and potential in the treatment of neuroendocrine tumors via peptide receptor radionuclide therapy (PRRT) using one or both of Y-90 and Lu-177-labeled peptides. Given the presence of different tumor sizes in patients and differing radionuclide dose delivery properties, the present study aims to use Monte Carlo simulations to estimate S-values to spherical tumors of various sizes with Y-90 and Lu-177 separately and in combination. The goal is to determine ratios of Y-90 to Lu-177 that result in the largest absorbed doses per decay of the radionuclides and the most suitable dose profiles to treat tumors of specific sizes. Material and methods Particle transfer calculations and simulations were performed using the Monte Carlo GATE simulation software. Spherical tumors of different sizes, ranging from 0.5 to 20 mm in radius, were designed. Activities of Lu-177 and Y-90, individually and in combination, were homogeneously placed within the total volume of the tumors. We determined the S-values to the tumors, and to the external volume outside of the tumors (cross-dose) which was used to approximate background tissue. The dose profiles were obtained for each of the different tumor sizes, and the uniformity of dose within each tumor was calculated. Results For all tumor sizes, the self-dose and cross-dose per decay from Y-90 were higher than that from Lu-177. We observed that Lu-177 had the most uniform dose distribution within tumors with radii less than 5 mm. For tumors greater than 5 mm in radius, a ratio of 25% Y-90 to 75% Lu-177 resulted in the most uniform doses. When the ratio of Lu-177 to Y-90 was smaller, the uniformity improved more with increasing tumor size. The cross-dose stayed approximately constant for tumors larger than 15 mm for all ratios of Lu-177 to Y-90. Finally, as the size of the tumor increased, differences in the S-values between different ratios of Lu-177 to Y-90 decreased. Conclusion Our work showed that to achieve a more uniform dose distribution within the tumor, Lu-177 alone is more effective for small tumors. For medium and large tumors, a ratio of Y-90 to Lu-177 with more or less Lu-177, respectively, is recommended.
引用
收藏
页码:646 / 655
页数:10
相关论文
共 50 条
  • [41] Targeted radionuclide therapy with RAFT-RGD radiolabelled with 90Y or 177Lu in a mouse model of αvβ3-expressing tumours
    Bozon-Petitprin, A.
    Bacot, S.
    Gauchez, A. S.
    Ahmadi, M.
    Bourre, J. C.
    Marti-Batlle, D.
    Perret, P.
    Broisat, A.
    Riou, L. M.
    Claron, M.
    Boturyn, D.
    Fagret, D.
    Ghezzi, Catherine
    Vuillez, J. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) : 252 - 263
  • [42] Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects-polish multicenter experience
    Kunikowska, Jolanta
    Zemczak, Anna
    Kolodziej, Maciej
    Guts, Pawel
    Lon, Izabela
    Pawlak, Dariusz
    Mikolajczak, Renata
    Kaminski, Grzegorz
    Ruchala, Marek
    Kos-Kudla, Beata
    Krolicki, Leszek
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 922 - 933
  • [43] Remarkable regression of inoperable pancreatic grade 3 neuroendocrine neoplasm after radioligand therapy with [177Lu]LuDOTATAT E and [90Y]YDOTATATE
    Durma, Adam D.
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Kaminski, Grzegorz
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2023, 133 (11):
  • [44] Evaluation of the skin doses absorbed by operators involved in 90Y and 177Lu handling
    Grassi, E.
    Fioroni, F.
    Sarti, M.
    Versari, A.
    Iori, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S272 - S273
  • [45] 90Y/177Lu-DOTATATE therapy: survival of the fittest?
    Boudewijn Brans
    Felix M. Mottaghy
    Alfons Kessels
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 1785 - 1787
  • [46] The Influence of the Sizes of Nanodiamond Aggregates in Suspensions on the Efficiency of Sorption of 90Y and 177Lu Isotopes for Further Use in Nuclear Medicine
    Kazakov, A. G.
    Babenya, J. S.
    Ekatova, T. Y.
    Vinokurov, S. E.
    Khvorostinin, E. Y.
    Ushakov, I. A.
    Zukau, V. V.
    Stasyuk, E. S.
    Nesterov, E. A.
    Sadkin, V. L.
    Rogov, A. S.
    Myasoedov, B. F.
    RADIOCHEMISTRY, 2024, 66 (02) : 198 - 205
  • [47] 90Y and 177LU labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy
    Liu, S
    Cheung, E
    Ziegler, MC
    Rajopadhye, M
    Edwards, DS
    BIOCONJUGATE CHEMISTRY, 2001, 12 (04) : 559 - 568
  • [48] Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y:: Peptide receptor radionuclide therapy results in vitro
    Capello, A
    Krenning, EP
    Breeman, WAP
    Bernard, BF
    Konijnenberg, MW
    de Jong, M
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (05) : 761 - 768
  • [49] 90Y/177Lu-DOTATATE therapy: survival of the fittest?
    Brans, Boudewijn
    Mottaghy, Felix M.
    Kessels, Alfons
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (10) : 1785 - 1787
  • [50] Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
    Urso, Luca
    Panareo, Stefano
    Castello, Angelo
    Ambrosio, Maria Rosaria
    Zatelli, Maria Chiara
    Caracciolo, Matteo
    Tonini, Eugenia
    Valpiani, Giorgia
    Boschi, Alessandra
    Uccelli, Licia
    Cittanti, Corrado
    Bartolomei, Mirco
    PHARMACEUTICS, 2022, 14 (10)